Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 11/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 11/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509856 | 0.73 | HSD11B1 (0.58) | HSD11B1 | |
| SCHEMBL2772572 | 0.70 | KDM4E (0.41) | KMT2AMEN1KCNJ5KCNJ3NOTUM | |
| SCHEMBL498571 | 0.69 | ALDH1A1 (0.39) | P2RX7HSD11B1KMT2AMEN1 | |
| SCHEMBL2772721 | 0.67 | KCNJ5 (0.39) | KMT2AMEN1KCNJ5KCNJ3 | |
| SCHEMBL497962 | 0.67 | GABRB3 (0.47) | KCNJ5KCNJ3NOTUM | |
| SCHEMBL2771556 | 0.64 | PDE4B (0.39) | P2RX7KMT2AMEN1KCNJ5KCNJ3 | |
| SCHEMBL4195851 | 0.64 | HSD11B1 (0.61) | P2RX7HSD11B1 | |
| SCHEMBL498227 | 0.64 | NR1H4 (0.47) | KCNJ5KCNJ3NOTUM | |
| SCHEMBL497822 | 0.64 | GABRB3 (0.51) | NOTUM | |
| SCHEMBL2131569 | 0.64 | NOTUM (0.42) | KCNJ5KCNJ3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | P2RX7 1163/4885HSD11B1 81/4885KMT2A 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.